Bedaquiline-containing regimens and multidrug-resistant tuberculosis: a systematic review and meta-analysis

Multidrug-resistant tuberculosis (MDR-TB) is a life-threatening infectious disease. Treatment requires multiple antimicrobial agents used for extended periods of time. The present study sought to evaluate the treatment success rate of bedaquiline-based regimens in MDR-TB patients. This was a systema...

Full description

Saved in:
Bibliographic Details
Published in:Jornal brasileiro de pneumologia 2022-01, Vol.48 (2), p.e20210384-e20210384
Main Authors: Hatami, Hossein, Sotgiu, Giovanni, Bostanghadiri, Narjess, Abadi, Sahel Shafiee Dolat, Mesgarpour, Bita, Goudarzi, Hossein, Migliori, Giovanni Battista, Nasiri, Mohammad Javad
Format: Article
Language:English
Subjects:
Drug resistance
Efficacy
RESPIRATORY SYSTEM
Systematic Review and Meta-Analysis
Tuberculosis
Tuberculosis, multidrug-resistant
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Multidrug-resistant tuberculosis (MDR-TB) is a life-threatening infectious disease. Treatment requires multiple antimicrobial agents used for extended periods of time. The present study sought to evaluate the treatment success rate of bedaquiline-based regimens in MDR-TB patients. This was a systematic review and meta-analysis of studies published up to March 15, 2021. The pooled treatment success rates and 95% CIs were assessed with the fixed-effect model or the random-effects model. Values of p < 0.05 were considered significant for publication bias. A total of 2,679 articles were retrieved by database searching. Of those, 29 met the inclusion criteria. Of those, 25 were observational studies (including a total of 3,536 patients) and 4 were experimental studies (including a total of 440 patients). The pooled treatment success rate was 74.7% (95% CI, 69.8-79.0) in the observational studies and 86.1% (95% CI, 76.8-92.1; p = 0.00; I2 = 75%) in the experimental studies. There was no evidence of publication bias (p > 0.05). In patients with MDR-TB receiving bedaquiline, culture conversion and treatment success rates are high even in cases of extensive resistance.
ISSN:1806-3756
1806-3713
1806-3756
DOI:10.36416/1806-3756/e20210384